Clinical trials: Melanoma of Skin
CRC (Colorectal Cancer), Melanoma (Skin Cancer)
A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary antitumor activity of TGI-5 as monotherapy and in combination with Nivolumab in subjects with…
- Conditions
- CRC (Colorectal Cancer), Melanoma (Skin Cancer), HCC - Hepatocellular Carcinoma, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- TGI5 (NCT07376707)
- Testing
- TGI-5
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Hefei TG ImmunoPharma Co., Ltd.
Melanoma
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation.
- Trial name
- NCT03455764
- Testing
- MCS110, Dabrafenib, Trametinib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Melanoma
TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)
This is a single center, single arm phase I trial to test the feasibility and safety of Tumor- Infiltrating Lymphocyte-Adoptive Cell Therapy (TIL-ACT) followed by nivolumab rescue in unresectable locally advanced or metastatic…
- Trial name
- NCT03475134
- Testing
- TIL, Cyclophosphamide, Fludarabine
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Malignant Melanoma
Anesthesia and Cancer Recurrence im Malignant Melanoma
Studies in animals and retrospective studies in humans show that regional anesthesia reduces metastatic cancer dissemination. The investigators hypothesize that in patients suffering from malignant melanoma who have to undergo…
- Trial name
- NCT01588847
- Testing
- Spinal anesthesia with Bupivacaine hyperbar 0.5 %, General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane
- Where
- Germany
- Volunteers
- 230 people
- Sponsor
- University Hospital Muenster
Melanoma
Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma
The purpose of this study is to test the safety of an investigational combination drug/immunotherapy for the treatment of Stage III/IV melanoma.
- Trial name
- NCT00815607
- Testing
- INXN-1001, INXN-3001
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Alaunos Therapeutics
Melanoma, Squamous Cell Carcinoma of the Head and Neck
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
The purpose of this study is to test the safety of a course of injections containing Poly-ICLC in patients with advanced solid tumors that can be easily and safely reached with a needle.
- Conditions
- Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin, Sarcoma of the Skin
- Trial name
- Hiltonol (NCT01984892)
- Testing
- Poly-ICLC
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Nina Bhardwaj
Malignant Neoplasm of Breast, CNS Malignancy
Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
This phase I trial using the EffTox design will evaluate activity and safety of alisertib, an Aurora A kinase inhibitor, when given in combination with the selective VEGFR inhibitor pazopanib in patients with advanced, previously…
- Conditions
- Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm of Gastrointestinal Tract, Genitourinary Neoplasms Malignancy and Gender Unspecified
- Trial name
- NCT01639911
- Testing
- Alisertib, Pazopanib
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Illinois Chicago
Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by…
- Trial name
- NCT02339571
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 763 sites in United States
- Volunteers
- 600 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma
Treatment of disseminated melanoma is still a difficult issue. Obvious achievements of recent years proves efficacy of immunologic approachees in this field.
- Trial name
- NCT02190838
- Testing
- Metformin, Melatonin, Dacarbazine
- Where
- 3 sites in Russia
- Volunteers
- 57 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Melanoma, Lung Cancer
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
This is an observational, multicenter study in participants treated with nivolumab for the approved indications of melanoma and Lung cancer in Australia, the EU, Switzerland, the United Kingdom (UK), and the United States (US).
- Trial name
- NCT02847728
- Where
- 94 sites in United States, Australia and 12 more
- Volunteers
- 1,189 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
The Prognostic Value of 18F-PFPN PET Imaging in Patients With Malignant Melanoma
This is a monocentric prospective study. This study aims to investigate the prognostic value of the novel melanin-targeted imaging modality 18F-PFPN PET in patients with melanoma and seek independent prognostic factors for…
- Trial name
- NCT05645484
- Testing
- 18F-PFPN, 18F-FDG
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Melanoma
Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC)
Over the past few years it has become evident that cancer cells can be recognized by the patient's own immune system. The immunological mechanisms at play are often referred to as the "cancer immune cycle" (Chen and Mellman 2013…
- Trial name
- myDCTV (NCT03747744)
- Testing
- CD1c (BDCA-1)+ myDC
- Where
- Belgium
- Volunteers
- 18 people
- Sponsor
- Universitair Ziekenhuis Brussel
Melanoma
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
This study will examine the effectiveness and safety of glembatumumab vedotin as monotherapy or in combination with immunotherapies in patients with advanced melanoma.
- Trial name
- NCT02302339
- Testing
- glembatumumab vedotin, glembatumumab vedotin and varlilumab, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)
- Where
- 14 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Cancer
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00900302
- Testing
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- OHSU Knight Cancer Institute
Melanoma, Adjuvant
Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection
The purpose of this Treatment Plan is to allow access to trametinib and dabrafenib for eligible high-risk BRAF mutation-positive patients in the adjuvant treatment of melanoma after surgical resection.
- Trial name
- NCT04544202
- Testing
- Dabrafenib and Trametinib, Dabrafenib, Trametinib
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer, Melanoma
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)
The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in participants with NSCLC.
- Conditions
- Non-Small Cell Lung Cancer, Melanoma, Mismatch Repair-Proficient Colorectal Cancer
- Trial name
- NCT02437136
- Testing
- entinostat, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 191 people
- Sponsor
- Syndax Pharmaceuticals
Metastatic Melanoma, Advanced Melanoma
XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy
This is a first-in-human, multi-center, multi-cohort, open-label, phase Ib/II study of XmAb22841 (CTLA-4 X LAG3) administered in combination with XmAb23104 (PD1 X ICOS) in participants with a histologically or cytologically…
- Trial name
- NCT05695898
- Testing
- XmAb22841, XmAb23104
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Melanoma
Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00466687
- Testing
- bevacizumab, erlotinib hydrochloride, fluorescence in situ hybridization
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Metastatic Melanoma
Dose Escalation Study of MLN4924 in Adults With Melanoma
This is an open-label, multicenter, phase 1, dose escalation study that will evaluate the safety profile, establish Maximum Tolerated Dose (MTD), and inform the recommended phase 2 dose of MLN4924 as well as evaluate antitumor…
- Trial name
- NCT01011530
- Testing
- MLN4924
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.